A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration | Zendy

Tom Aaberg | Zendy; Patrick D. Williams | Zendy; David Callanan | Zendy; Wayne Solley | Zendy; Robert L. Avery | Zendy; Dante J. Pieramici | Zendy

Open Access

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

Author(s) -

Tom Aaberg,

Patrick D. Williams,

David Callanan,

Wayne Solley,

Robert L. Avery,

Dante J. Pieramici

Publication year - 2012

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s31010

Subject(s) - ranibizumab , medicine , macular degeneration , ophthalmology , photodynamic therapy , bevacizumab , surgery , chemotherapy , chemistry , organic chemistry

This prospective multi-center pilot study compares the use of half-fluence photodynamic therapy combined with ranibizumab with ranibizumab monotherapy for the treatment of neovascular age-related macular degeneration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research